ArticleNeurology2017
Small vessel disease burden in cerebral amyloid angiopathy without symptomatic hemorrhage.
Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Pooled it
- Plasma p-tau217 detects Alzheimer's disease co-pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Using radiological brain health to predict recurrence after ischemic stroke and transient ischemic attack: A population-based study.Neurology open access · 2026Article
- CSF Biomarker Profile of Cerebral Amyloid Angiopathy: Diagnostic Performance and Imaging Correlates in a Hospital-Based Neurology Cohort.European journal of neurology · 2026Article
- Sex-specific risk factors and clinical dementia outcomes for white matter hyperintensities in a large South Korean cohort.Alzheimer's research & therapy · 2024Observational
- Higher HbA1c Is Associated With Greater 2-Year Progression of White Matter Hyperintensities.Diabetes · 2024Article
- The Association Between Positive Amyloid-PET and Cognitive Decline Is Not Always Supportive of Alzheimer's Disease: Suggestions from a Case Report.Journal of Alzheimer's disease reports · 2024Article
- Cerebral Proteomic Changes in the rTg-D Rat Model of Cerebral Amyloid Angiopathy Type-2 With Cortical Microhemorrhages and Cognitive Impairments.Neuroscience insights · 2024Article
- Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy.Brain communications · 2023Article
- Brain Enlarged Perivascular Spaces as Imaging Biomarkers of Cerebrovascular Disease: A Clinical Narrative Review.Journal of the American Heart Association · 2022Review
- Dissecting Polygenic Etiology of Ischemic Stroke in the Era of Precision Medicine.Journal of clinical medicine · 2022Review
- Predicting mortality among ischemic stroke patients using pathways-derived polygenic risk scores.Scientific reports · 2022Article
- Review
- White Matter Free Water is a Composite Marker of Cerebral Small Vessel Degeneration.Translational stroke research · 2022Article
- Chronic kidney disease correlates with MRI findings of cerebral small vessel disease.Renal failure · 2021Article
- Association of Cerebral Small Vessel Disease and Cognitive Decline After Intracerebral Hemorrhage.Neurology · 2021Article
- Tau reduction in aged mice does not impact Microangiopathy.Acta neuropathologica communications · 2020Article
- Investigating APOE, APP-Aβ metabolism genes and Alzheimer's disease GWAS hits in brain small vessel ischemic disease.Scientific reports · 2020Article
- Small vessel disease in patients with subarachnoid hemorrhage: Prevalence and associations with vasospasm occurrence, severity and clinical outcomes.The neuroradiology journal · 2019Article
- Cortical Superficial Siderosis Evolution.Stroke · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 3 countries.
Funding
Abstract
objectiveCerebral amyloid angiopathy (CAA) is a common age-related small vessel disease (SVD). Patients without intracerebral hemorrhage (ICH) typically present with transient focal neurologic episodes (TFNEs) or cognitive symptoms. We sought to determine if SVD lesion burden differed between patients with CAA first presenting with TFNEs vs cognitive symptoms.
methodsA total of 647 patients presenting either to a stroke department (n = 205) or an outpatient memory clinic (n = 442) were screened for eligibility. Patients meeting modified Boston criteria for probable CAA were included and markers of SVD were quantified, including cerebral microbleeds (CMBs), perivascular spaces, cortical superficial siderosis (cSS), and white matter hyperintensities (WMHs). Patients were classified according to presentation symptoms (TFNEs vs cognitive). Total CAA-SVD burden was assessed using a validated summary score. Individual neuroimaging markers and total SVD burden were compared between groups using univariable and multivariable models.
resultsThere were 261 patients with probable CAA included. After adjustment for confounders, patients first seen for TFNEs (n = 97) demonstrated a higher prevalence of cSS (
conclusionsPatients with probable CAA without ICH first evaluated for TFNEs bear a higher burden of structural MRI SVD-related damage compared to those first seen for cognitive symptoms. This study sheds light on neuroimaging profile differences across clinical phenotypes of patients with CAA without ICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.